Redoxis Overview
- Year Founded
-
2007
- Status
-
Private
- Employees
-
24
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$905K
- Investors
-
4
Redoxis General Information
Description
Operator of pre-clinical research facilities intended to offer preclinical research, immunology, and in vivo studies. The company's platform focuses on preclinical drug development and efficacy evaluation in models of inflammatory and autoimmune diseases with strong roots in academic research, enabling healthcare professionals with tools for the investigation of therapeutic efficacy and mode of action of novel therapies.
Contact Information
Website
www.redoxis.seCorporate Office
- Scheelevägen 2
- Medicon Village
- 223 81 Lund
- Sweden
Corporate Office
- Scheelevägen 2
- Medicon Village
- 223 81 Lund
- Sweden
Redoxis Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Grant | 11-Jan-2022 | $905K | Completed | Generating Revenue | ||
| 3. Grant | 10-Sep-2019 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 30-Jun-2008 | Completed | Generating Revenue | |||
| 1. Accelerator/Incubator | Completed | Startup |
Redoxis Patents
Redoxis Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2008330225-A1 | New treatment of autoimmune conditions | Inactive | 28-Nov-2007 | ||
| CA-2706849-A1 | New treatment of autoimmune conditions | Inactive | 28-Nov-2007 | ||
| EP-2212701-A1 | New treatment of autoimmune conditions | Inactive | 28-Nov-2007 | ||
| EP-2212701-A4 | New treatment of autoimmune conditions | Inactive | 28-Nov-2007 | ||
| US-20110200993-A1 | New treatment of autoimmune conditions | Inactive | 28-Nov-2007 | G01N33/5035 |
Redoxis Signals
Redoxis Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| EUREKA Eurostars | Government | |||
| European Commission | Government | |||
| Sätila Impact Investment | Impact Investing | Minority | ||
| SmiLe Incubator | Accelerator/Incubator | Minority |
Redoxis Acquisitions (1)
Redoxis’s most recent deal was a Merger/Acquisition with ProNoxis. The deal was made on 26-Nov-2012.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| ProNoxis | 26-Nov-2012 | Merger/Acquisition | Drug Discovery |
Redoxis FAQs
-
When was Redoxis founded?
Redoxis was founded in 2007.
-
Where is Redoxis headquartered?
Redoxis is headquartered in Lund, Sweden.
-
What is the size of Redoxis?
Redoxis has 24 total employees.
-
What industry is Redoxis in?
Redoxis’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is Redoxis a private or public company?
Redoxis is a Private company.
-
What is Redoxis’s current revenue?
The current revenue for Redoxis is .
-
Who are Redoxis’s investors?
EUREKA Eurostars, European Commission, Sätila Impact Investment, and SmiLe Incubator have invested in Redoxis.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process